FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| 1. Name ar Dowde (Last) C/O ENT 6 TIDE S (Street) BOSTON | 2. I Et | 2. Issuer Name and Ticker or Trading Symbol Entrada Therapeutics, Inc. [TRDA] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2023 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director | | | | | | | | | |
|--|--|--|---|------|------------------------------|-----------------|--------|------|--|--|---|----------------------|--|-------|--|--|------------------------------------|--|---------------------------------------|
| (City) | (S | tate) | (Zip) | | | | | | | 1 010011 | Person | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/ | | | | | | Execution Date, | | | | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a | | nd 5) Securiti Benefic Owned | | es ally Following | Form (D) o | n: Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | | Code | v | Amount | (A) or (D) | Price | Reporte Transac (Instr. 3 | | tion(s) | | | | |
| Common Stock 03/01/20 | | | | | | 023 | | A | | 28,400(1) | A | \$ <mark>0</mark> (1 | .1) 73 | | ,683 | | D | | |
| Common Stock 03/02/20 | | | | 2023 | 023 | | F | | 1,028(2) | D | \$11.59 | 1.5962 72 | | 2,655 | | D | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | | 4. Transa Code (8) | | | | 6. Date Exercisab Expiration Date (Month/Day/Year) | | te of Securities | | ies g Security | D | 3. Price of Derivative Security Instr. 5) | 9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | illy | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) |
| | | | | | Code | v | (A) | (D) | Date Exercis | sable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Stock Option (Right to Buy) | \$12.25 | 03/01/2023 | | | A | | 43,000 | | (3) | | 03/01/2033 | Common Stock | 43,000 |) | \$0 | 43,000 |) | D | |

Explanation of Responses:

- 1. Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
- 2. This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
- 3. 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027.

Remarks:

/s/ Jared Cohen, as Attorney-in-03/03/2023 **Fact**

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.